Surghive
Manufacturer-independent immersive VR/AR and mobile training for robotic surgeons and operating-room teams.
Website: https://surghive.com/
Cover Block
From the public record
| Field | Value |
|---|---|
| Name | Surghive |
| Tagline | Manufacturer-independent immersive VR/AR and mobile training for robotic surgeons and operating-room teams. |
| Headquarters | Teesside, UK |
| Founded | 2022 |
| Stage | Pre-Seed |
| Business model | SaaS |
| Industry | Healthtech |
| Technology | Software (Non-AI) |
| Geography | Western Europe |
| Growth profile | Venture Scale |
| Founding team | Co-Founders (3+) |
| Funding label | Undisclosed |
Links
From the public record
The Short Version
PUBLIC Surghive is building manufacturer-independent VR, AR, and mobile training software for robotic surgeons and operating-room teams, and it merits investor attention now because public reporting shows both early institutional backing and a planned national pilot in a part of surgical training that remains fragmented by device vendor [Tees Business, June 2026] [Entrepreneurs’ Forum, October 2026] [Medilink, October 2026]. Founded in Teesside in 2022, and previously referred to as Robohive in local coverage, the company appears to have emerged from a clinician-led view that access to robotic surgery training is constrained by equipment availability and manufacturer-specific pathways [Tees Business, June 2026] [Tees Valley Combined Authority, September 2026].
The product thesis is straightforward: immersive simulation paired with a digital learning layer that can support training across robotic platforms rather than within a single OEM ecosystem, a positioning echoed across local authority, trade, and employer-adjacent coverage [The Northern Echo, September 2026] [Tees Valley Combined Authority, September 2026] [Medilink, October 2026]. That differentiation is promising if procurement buyers want broader access and lower dependence on robot time, but the commercial proof point still sits ahead, with public sources pointing to a 2027 product target and a pilot cohort of more than 100 committed surgeons that has not yet translated into named paying customers in the available reporting [Tees Business, June 2026] [Entrepreneurs’ Forum, October 2026].
The founding team is relevant to the problem set. Public materials identify co-founders Dr Rachael Coates and Professor Deena Pravin Harji as surgeons, with Christi Anderson covering the commercial and finance side, and Medilink reported in October 2026 that Andy Wood joined as chairman to strengthen strategy, governance, customer development, and partnerships [Tees Valley Combined Authority, September 2026] [Bdaily, October 2026] [Medilink, October 2026].
On capitalization, the company has disclosed backing from SFC Capital and the Chadda Family, plus a £40,000 Tees Valley Innovation Voucher, but not a round size or valuation in the cited public materials [Entrepreneurs’ Forum, October 2026] [The Northern Echo, September 2026].
Single-source, plausible -- Core company, funding, voucher, and chairman facts are supported by named public sources, but several operating claims, including pilot commitment and launch timing, rely on single-source or company-adjacent reporting.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Pre-Seed |
| Business Model | SaaS |
| Industry / Vertical | Healthtech |
| Technology Type | Software (Non-AI) |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding | Undisclosed |
The Company in Brief
PUBLIC Surghive is a Teesside, UK-based healthtech software startup focused on training for robotic surgeons and operating-room teams, with company materials and regional coverage describing a manufacturer-independent approach to digital surgical education [Tees Valley Combined Authority, September 2026]. The company is identified as founded in 2022, and public reporting indicates it previously operated under the name Robohive before adopting the Surghive brand [Tees Business, June 2026].
The public record is still thin, but the chronology is reasonably clear. In June 2026, regional business coverage reported that Surghive was preparing a national pilot and targeting a commercial product launch in 2027 [Tees Business, June 2026]. In September 2026, the company was named as a recipient of a £40,000 Tees Valley Innovation Voucher to support development of its digital surgical training platform [The Northern Echo, September 2026; Tees Valley Combined Authority, September 2026]. In October 2026, Entrepreneurs' Forum reported backing from SFC Capital and the Chadda Family, and Medilink separately reported the appointment of Andy Wood as chairman [Entrepreneurs’ Forum, October 2026; Medilink, October 2026].
Single-source, plausible -- Confirmed by multiple named publishers for headquarters, timeline, voucher funding, investor names, and chairman appointment, but this section does not rely on Crunchbase, company website, or state filings as specified.
What They Have Built
MIXED
The product story is narrower than the category rhetoric around surgical simulation, which is usually a good place to start. Surghive is publicly described as building manufacturer-independent training software for robotic surgeons and operating-room teams, with delivery across VR, AR and mobile rather than through a single hardware vendor's stack [Tees Business, June 2026] [Medilink, October 2026] [Tees Valley Combined Authority, September 2026]. That platform-independence matters because the stated problem is fragmentation in manufacturer-specific training and limited access to physical robotic systems for practice, a constraint the company says it wants to ease with software-led training pathways [Tees Business, June 2026] [Tees Valley Combined Authority, September 2026].
The public feature set is still early, but it is more concrete than a one-line simulation claim. Regional and sector coverage describes a virtual reality and digital learning ecosystem, plus an app intended to connect surgeons to training content, competency requirements, learning opportunities and recommendations [The Northern Echo, September 2026] [Bdaily, October 2026]. Separate public profiles describe the product as immersive software training that works across robotic platforms and is designed to let clinicians practice without waiting for operating-room equipment access [Medilink, October 2026] [Teesside University, 2026] [Sujata Gupta - Manchester University NHS Foundation Trust | LinkedIn] [Adam Levick - Greater Sheffield Area | Professional Profile | LinkedIn]. A commercial launch target for 2027 has been reported, but there is no verified public demo detail here on fidelity, assessment methodology, device integrations, or regulatory positioning, so those remain diligence items rather than established capabilities [Tees Business, June 2026].
Single-source, plausible -- Product modality and platform-independence are corroborated by Tees Business, Medilink, Bdaily, The Northern Echo, and Tees Valley Combined Authority; feature depth and technical implementation remain only partially described in public sources.
Market Size and Demand
From the public record
Robotic surgery training is drawing attention because procedure volume, platform diversity, and workforce bottlenecks are moving faster than the current training infrastructure, at least in the public evidence available around Surghive's launch market [Tees Business, June 2026] [Tees Valley Combined Authority, September 2026].
The constraint in this section is straightforward: the supplied source set does not include a named third-party TAM, SAM, or SOM study for robotic surgery training itself. That leaves market sizing indirect rather than definitive. The cleanest read is to anchor on the problem statements repeated across public coverage, namely that robotic-surgery training remains fragmented, often tied to individual manufacturers, and limited by access to physical hospital equipment and expert supervision [Tees Business, June 2026] [The Northern Echo, September 2026] [Medilink, October 2026]. In that framing, Surghive sits at the intersection of several adjacent markets rather than a single neatly measured one: surgical education software, simulation-based medical training, and the installed-base expansion of robotic-assisted surgery programs [Tees Valley Combined Authority, September 2026] [Bdaily, October 2026].
Demand signals in the public record are early but directionally useful. Tees Business reported in June 2026 that a national pilot was due to begin in August 2026 with more than 100 surgeons committed, which, if borne out, suggests there is at least pre-commercial willingness among clinicians to trial an alternative training format [Tees Business, June 2026]. Separate public descriptions from regional bodies and industry groups are consistent on the use case: widening access to specialist training, reducing dependence on scarce robot time, and supporting progress tracking, competency requirements, and learning pathways through a digital layer rather than only in-theatre instruction [The Northern Echo, September 2026] [Tees Valley Combined Authority, September 2026] [Bdaily, October 2026]. Those are credible tailwinds because they speak to throughput and access, two pressures hospital systems already understand.
The adjacent markets matter because Surghive does not need to own the full robotics stack to become relevant. Public reporting positions the company as manufacturer-independent training software for robotic surgeons and operating-room teams, which places its nearest economic substitutes not only in robot-maker training programs but also in broader medical simulation, continuing professional development tools, and hospital learning systems that can absorb competency tracking and digital content delivery [Medilink, October 2026] [Bdaily, October 2026]. That can expand the addressable budget surface over time, but it also means adoption may depend less on enthusiasm from individual surgeons and more on whether trusts, training bodies, and universities treat robotic training as a recurring software and curriculum spend rather than a one-off procedural expense [Tees Valley Combined Authority, September 2026] [The Whole Point].
Regulation and macro conditions are supportive in a narrow sense, even if the sources stop short of quantifying the effect. The public-sector voucher support in Tees Valley indicates local policy interest in digital capability building for specialist healthcare training, and the company has been described as developing infrastructure intended for NHS and broader training use cases [The Northern Echo, September 2026] [Tees Valley Combined Authority, September 2026] [Lucy Hansen - South Tees Hospitals NHS Trust | LinkedIn]. At the same time, healthcare procurement cycles, evidence thresholds, and integration into formal training pathways are likely to slow category development relative to ordinary enterprise software, especially where a product touches competency assessment and clinically sensitive workflows. The market can be real before it is fast.
| Cited market indicator | Figure | What it suggests |
|---|---|---|
| Innovation voucher awarded to Surghive | £40,000 | Public-sector willingness to fund early digital surgical training infrastructure [The Northern Echo, September 2026] |
| Surgeons reportedly committed to national pilot | 100+ | Early clinician interest before commercial launch, though still pre-revenue and pilot-stage [Tees Business, June 2026] |
The table is modest by design. It does not size the category, but it does show that the market case in public sources rests on two things: institutional willingness to subsidize experimentation and at least some reported clinician demand ahead of a 2027 commercial target [Tees Business, June 2026] [The Northern Echo, September 2026].
Inferred, not confirmed -- This section relies on regional news coverage, local authority reporting, and one company-adjacent interview for market inference; no named third-party TAM/SAM/SOM study was provided for robotic surgery training, so category sizing remains indirect rather than independently established.
Who Else Is Fighting for This
MIXED Surghive is positioning itself against two better-known alternatives by arguing that robotic-surgery training should sit above any single hardware vendor, rather than inside a manufacturer-specific pathway [Tees Business, June 2026] [Medilink, October 2026].
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| Surghive | Manufacturer-independent immersive VR, AR, and mobile training for robotic surgeons and operating-room teams | Seed investment disclosed in October 2026, amount undisclosed | Cross-platform training thesis, aimed at reducing dependence on access to a specific robot | [Entrepreneurs’ Forum, October 2026] [Tees Business, June 2026] [Medilink, October 2026] |
| Proximie | Digitally enabled surgery platform and remote collaboration software used around procedures | Stage and funding not established in the provided public source set | Broader workflow and intraoperative presence, if buyers prioritize connectivity around live surgery rather than simulation-first training | [Structured Facts] |
| Mimic Technologies | Surgical simulation and training software | Stage and funding not established in the provided public source set | Category familiarity in simulation-focused training, if buyers prefer an established simulation specialist | [Structured Facts] |
The competitive map breaks into three layers. First are incumbent pathways tied to robotic-system manufacturers, which Surghive explicitly frames as fragmented and access-constrained because training often sits close to a single device ecosystem [Tees Business, June 2026].
Surghive's edge today appears to be domain credibility plus a clear product wedge, not scale. Public reporting consistently ties the company to surgeon-founder leadership and to a manufacturer-independent training proposition, which is a useful starting point in a category where credibility with clinicians matters early [Tees Valley Combined Authority, September 2026] [Bdaily, October 2026]. That edge is real but still perishable: it becomes durable only if the national pilot converts into reference sites, evidence of competency improvement, or embedded institutional relationships. Public sources do not yet show those assets at scale [Tees Business, June 2026] [Entrepreneurs’ Forum, October 2026].
The exposure is easier to see than the moat. Surghive also does not appear, from public reporting, to own the robot OEM channel, which matters because manufacturers still shape surgeon onboarding and can influence where formal training spend lands [Tees Business, June 2026].
The most plausible 18-month scenario is a sorting of the market by buying center rather than by pure product quality. Surghive is the winner if hospitals, universities, and NHS-aligned training bodies decide that cross-platform access and off-robot practice are more important than staying inside any one manufacturer's curriculum, especially if the company can turn its reported surgeon interest into a visible pilot footprint [Tees Business, June 2026] [The Northern Echo, September 2026]. The loser if manufacturer lock-in persists is Surghive, because its central claim depends on buyers wanting independence.
Inferred, not confirmed -- This section combines multiple public sources for Surghive's positioning and development status, but competitor-specific details in the provided fact set are limited to named companies without independently sourced stage or product-depth corroboration.
Opportunity
PUBLIC The prize here is not a niche training app, but the chance to become the cross-platform training layer for robotic surgery, a part of the stack that could matter wherever hospitals, surgeons, and training bodies need skills development that is not tied to a single device maker [Tees Business, June 2026] [Medilink, October 2026].
Surghive’s clearest upside case is straightforward. If robotic surgery keeps expanding, and if training remains fragmented across manufacturer-specific pathways, a neutral software layer that helps surgeons and operating-room teams train across systems could become part of how institutions operationalize adoption at scale [Tees Business, June 2026] [Medilink, October 2026]. The public record is still early, but it is not empty: the company has articulated a manufacturer-independent position, reported more than 100 surgeons committed to a national pilot, secured backing from SFC Capital and the Chadda Family, and won non-dilutive support through a £40,000 Tees Valley Innovation Voucher [Tees Business, June 2026] [Entrepreneurs’ Forum, October 2026] [The Northern Echo, September 2026]. That combination does not prove commercial pull, but it does make the upside path reachable rather than purely conceptual.
The strongest version of the opportunity is that Surghive becomes default infrastructure for robotic-surgery training outside any single robot OEM’s walled garden. That would place it closer to a category utility than a point solution. The logic rests on two public signals. First, multiple sources describe the product as platform-agnostic and aimed at improving access where time on hospital equipment is limited [Tees Valley Combined Authority, September 2026] [Bdaily, October 2026]. Second, the company is targeting a 2027 commercial product after preparing a national pilot, which suggests management is trying to move from prototype narrative to workflow adoption on a defined timetable [Tees Business, June 2026].
| Scenario | What happens | Catalyst | Why its plausible |
|---|---|---|---|
| Cross-platform NHS training layer | Surghive becomes a recurring software provider for NHS-aligned robotic training pathways, used by surgeons and theatre teams across multiple sites and specialties. | The national pilot beginning in August 2026 converts committed surgeons into reference users and institutional buyers [Tees Business, June 2026]. | Public reporting says more than 100 surgeons had already committed to the pilot, and the product is framed around improving access to specialist training across the NHS and beyond [Tees Business, June 2026] [Bdaily, October 2026]. |
| Embedded partner to robot manufacturers and training bodies | The company remains independent but is adopted as a complementary training layer by manufacturers, universities, and training organisations that need a neutral software environment. | A commercial launch in 2027 combined with formal partnerships that validate cross-platform use [Tees Business, June 2026]. | Surghive has described intended engagement with surgeons, training organisations, universities, NHS stakeholders, and robotic-surgery manufacturers, and its differentiation is explicitly tied to training irrespective of the robotic system used [Tees Valley Combined Authority, September 2026] [Medilink, October 2026]. |
| Evidence-led surgical skills platform | Surghive extends from simulation into competency tracking, skills-gap identification, and personalized learning workflows that become harder to replace once institutions map their training requirements into the system [The Northern Echo, September 2026]. | The app and broader digital learning ecosystem launch as more than content delivery, creating administrative and compliance value alongside simulation [The Northern Echo, September 2026] [Bdaily, October 2026]. | The public descriptions already go beyond VR simulation alone, referencing competency requirements, recommendations, and a digital learning ecosystem, which is the shape of a broader software system rather than a one-off module [The Northern Echo, September 2026] [Bdaily, October 2026]. |
These scenarios point to the same compounding mechanism. A first cohort of surgeons creates proof of use, which can help win institutional trust. Institutional trust can then support partnerships with training bodies, hospitals, and potentially manufacturers. Once those groups start using the software not only for immersive practice but also for competency requirements, progress tracking, and skills-gap checks, the product has more surfaces to retain users and justify expansion [The Northern Echo, September 2026] [Bdaily, October 2026]. The early signs of that flywheel are modest but visible in public: a reported national pilot, a product scope that spans simulation and learning management, and external supporters willing to fund continued development [Tees Business, June 2026] [The Northern Echo, September 2026] [Entrepreneurs’ Forum, October 2026].
The size of the win is best framed as a scenario, not a forecast. No public market-sizing source was provided in the research, and there is no verified revenue base yet, so precision would be false. Still, a useful public comparable is Proximie, a UK surgical technology company named here as a competitor, which has raised substantial institutional capital over multiple rounds and built a broad platform narrative around digitally enabled surgery [Crunchbase, April 2025]. If Surghive were to become a recognized cross-platform training infrastructure company for robotic surgery, rather than a service-led content vendor, the outcome could plausibly be venture-scale and strategically relevant to medtech, surgical education, or hospital software buyers. In that scenario, it could support a meaningfully larger enterprise value than a narrow simulation tool, potentially in the range usually associated with scaled category software assets in surgical workflow and training, though no numerical valuation range can be defended from the public evidence here (scenario, not a forecast) [Crunchbase, April 2025] [Medilink, October 2026].
Single-source, plausible -- Relies on company-related public reporting from Tees Business, Medilink, Bdaily, The Northern Echo, Tees Valley Combined Authority, and Entrepreneurs’ Forum; competitor context is partially corroborated by Crunchbase, but commercial traction and product breadth remain only partially independently verified.
Sources
From the public record
[Tees Business, June 2026] Pitch perfect Surghive clinches Tech Start-Up prize. | https://teesbusiness.co.uk/2026/06/16/pitch-perfect-surghive-clinches-tech-start-up-prize/
[Entrepreneurs’ Forum, October 2026] Robotic surgery training company set to scale with new investment | https://entrepreneursforum.net/news/member-news/robotic-surgery-training-company-set-to-scale-with-new-investment/
[Medilink, October 2026] Surgery Training Company SURGHIVE Appoints Andy Wood as Chairman. | https://medilink.co.uk/news-surghive-andy-woods/
[The Northern Echo, September 2026] £1.5m scheme to boost Tees Valley digital and creative firms. | https://www.thenorthernecho.co.uk/news/26559517.1-5m-scheme-boost-tees-valley-digital-creative-firms/
[Tees Valley Combined Authority, September 2026] High Demand As First Firms Land Investment Zone Innovation Vouchers. | https://teesvalley-ca.gov.uk/news/high-demand-as-first-firms-land-investment-zone-innovation-vouchers/
[Bdaily, October 2026] Tech firm secures funding to pioneer surgical training. | https://bdaily.co.uk/articles/2026/10/13/tech-firm-secures-funding-to-pioneer-surgical-training
[Teesside University, Retrieved 2026] High demand as first firms land Investment Zone Innovation Vouchers | https://www.tees.ac.uk/sections/news/pressreleases_story.cfm?story_id=8777
[The Whole Point] Elevate Series - Dr Rachael Coates and Christi Anderson (CEO and COO of Surghive). | https://thewholepoint.co.uk/elevate-series-dr-rachael-coates-and-christi-anderson-ceo-and-coo-of-surghive/
[Crunchbase, April 2025] Proximie | https://www.crunchbase.com/organization/proximie
Articles about Surghive
- After a Six-Figure Seed, Surghive Targets a 2027 Launch for Surgery Training — A Teesside startup, backed by SFC Capital, is building a virtual reality training layer for surgeons to practice on any robotic system before touching the real thing.